MiFIR Casts Ominous Shadow on European Horizon

MiFID II and MiFIR will subject investment firms to more stringent trade reporting requirements. Brian Collings outlines the impact.

brian-collings-torstone-technology
Brian Collings is CEO of London-based Torstone Technology.

The Markets in Financial Instruments Directive (MiFID) II Regulatory Technical Standards (RTS) and its accompanying regulation, the Markets in Financial Instruments Regulation (MiFIR), published in September 2015, are set to introduce sweeping changes to the trading of securities in Europe.

The Directive has expanded the scope and level of prescription of investment firms' transaction reporting obligations, creating areas of overlap with the European Market Infrastructure Regulation (EMIR) trade

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@waterstechnology.com or view our subscription options here: http://subscriptions.waterstechnology.com/subscribe

You are currently unable to copy this content. Please contact info@waterstechnology.com to find out more.

Sorry, our subscription options are not loading right now

Please try again later. Get in touch with our customer services team if this issue persists.

New to Waterstechnology? View our subscription options

Register for free

Access two articles, our IMD and Waters Wraps, plus a member newsletter. Find out more.

All fields are mandatory unless otherwise highlighted.

This address will be used to create your account

Removal of Chevron spells t-r-o-u-b-l-e for the C-A-T

Citadel Securities and the American Securities Association are suing the SEC to limit the Consolidated Audit Trail, and their case may be aided by the removal of a key piece of the agency’s legislative power earlier this year.

Most read articles loading...

You need to sign in to use this feature. If you don’t have a WatersTechnology account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here